ARTICLE | Finance

Regulatory Milestones

Highlights of Weekly Biotech Stock Moves

December 13, 2010 8:00 AM UTC

Orexigen Therapeutics Inc. (NASDAQ:OREX) gained $3.60 (75%) to $8.41 last week after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 that the benefit-risk profile of Contrave supports approval as a long-term treatment for obesity(see Cover Story).

Active Biotech AB (SSE:ACTI) jumped SEK42.25 (33%) to SEK171 on Thursday after laquinimod met the primary endpoint of significantly reducing annualized relapse rates in the Phase III ALLEGRO trial to treat relapsing-remitting multiple sclerosis. The stock gained SEK42.50 (35%) to SEK163 on the week (see B12)...